The Rhodium Catalysed Direct Conversion of Phenols to Primary Cyclohexylamines
作者:Patrick Tomkins、Carlot Valgaeren、Koen Adriaensen、Thomas Cuypers、Dirk E. De Vos
DOI:10.1002/cctc.201800486
日期:2018.9.7
Cyclohexylamines are important intermediates in chemical industry, which are currently produced from petrochemical sources. Phenols, however, are an attractive sustainable feedstock. We here demonstrate the transformation of phenols with ammonia to primary cyclohexylamines. In contrast to previously reported chemistry which used palladium catalysts, we here show that rhodium is an excellent catalyst
접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
申请人:KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)
公开号:KR20180137057A
公开(公告)日:2018-12-27
본 발명은 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 접합 피리미딘 유도체는 브루톤 티로신 키나제 또는 TMD80의 활성을 억제하는 능력이 우수하므로, 브루톤 티로신 키나제 활성과 관련된 질환, 특히 암 또는 자가면역질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.
This is the translated text in Chinese:
本发明涉及连接嘧啶衍生物,其制备方法以及包含其作为有效成分的布鲁替罗辛酪氨酸激酶活性相关疾病的预防或治疗药物组合物。根据本发明,连接嘧啶衍生物具有优越的抑制布鲁替罗辛酪氨酸激酶或TMD80活性的能力,因此可以用于预防或治疗与布鲁替罗辛酪氨酸激酶活性相关的疾病,特别是癌症或自身免疫性疾病。
Fused heterocyclic compounds useful as kinase modulators
申请人:Vaccaro Wayne
公开号:US20070078136A1
公开(公告)日:2007-04-05
Compounds having the formula (1), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof,
are usefuil as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR
3
, and R
1
, R
2
, R
3
, X and Y are as defined herein.
[EN] BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2<br/>[FR] COMPOSÉ BICYCLIQUE ET SON UTILISATION POUR INHIBER SUV39H2
申请人:ONCOTHERAPY SCIENCE INC
公开号:WO2017058503A1
公开(公告)日:2017-04-06
The present invention directs to a compound represented by formula (I).
本发明涉及一种由化学式(I)表示的化合物。
[EN] IRAK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'IRAK ET LEURS UTILISATION
申请人:NIMBUS IRIS INC
公开号:WO2012097013A1
公开(公告)日:2012-07-19
The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.